Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

Diagnosis of new-onset prostate neoplasia (any risk category according to EAU guidelines).
Histological confirmation of disease by prostate biopsies. Absence of neuroendocrine differentiation
Low volume of metastatic disease defined according to CHAARTED study criteria (\< of 4 bone metastases, absence of visceral metastases)
Patients without previous treatment of primary malignancy (e.g. previous radical prostatectomy, previous RT)
Patients treated with systemic therapy (ADT as monotherapy or in combination) for less than 6 months prior to enrolment
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Patients eligible for local treatment of primary malignancy and concomitant systemic therapy
Signature of informed consent

Inability or unwillingness to give written informed consent
High volume metastatic disease defined according to CHARTEED criteria
ECOG performance status \> 1
Patients included in other clinical trials
Contraindications to hormone/systemic therapy administration
Previous treatment of primary tumour (RP, RT or other treatment of primary tumour)

OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate